The 2026 American Association for Cancer Research (AACR) annual meeting showcased pivotal data from several biotech leaders, highlighted by Moderna’s impressive results in first-line melanoma. Their investigational antigen therapy, mRNA-4359, achieved an 83% overall response rate when combined with Keytruda, significantly outperforming historical ...

On this episode of INsights & OUTcomes, we sit down with Mark Larkin, real-world evidence expert at Vitaccess, to explore why the “gold standard” of clinical trials often falls short the moment a treatment hits the real world.

Eli Lilly and Company has announced positive topline results from ACHIEVE-4, the longest and largest Phase 3 study of Foundayo (orforglipron) to date. The trial, which enrolled over 2,700 participants with type 2 diabetes and elevated cardiovascular risk, successfully met its primary endpoint by demonstrating non-inferiority in major adverse cardi...

Bristol Myers Squibb (BMS) has officially launched Beeline Medicines, a precision immunology startup backed by $300 million in funding from Bain Capital. Emerging from stealth, the biotech is led by industry veteran Saqib Islam and enters the market with five inherited BMS assets. The company’s primary focus is developing targeted therapies for au...

The FDA has granted Travere Therapeutics the first-ever product approval for focal segmental glomerulosclerosis (FSGS), a rare condition that causes progressive kidney scarring and organ failure. Marketed as Filspari, the drug is now cleared for adults and children aged eight and older, potentially reaching an estimated 30,000 eligible patients in...